Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages. (August 2022)

• Record Type: Journal Article
• Authors: Akkus, Gulsum; Koyuturk, Leyla Canpolat; Yilmaz, Mustafa; Hancer, Serhat; Ozercan, Ibrahim Hanifi; Kuloglu, Tuncay
• Is Part Of: Tissue & cell. Volume 77(2022)
• Publication Date: 2022-08
• Subjects: Asprosin -- Histopathology -- Invasive ductal breast cancer -- Meteorin-like protein; Cytology -- Periodicals; 571.5
• DOI: 10.1016/j.tice.2022.101855
• Languages: English
• ISSNs: 0040-8166

Abstract

Abstract: Aim: The study aimed to investigate asprosin (ASP) and meteorin-like (METRNL) protein immunoreactivity in invasive ductal breast cancer. Materials and methods: Overall, 60 cases of invasive ductal breast cancer (20 cases each of Grade 1, 2 and 3) were evaluated in addition to 20 normal breast tissues obtained from the Pathology Department Archive. ASP and METRNL expressions were assessed using immunohistochemical staining and visualised under a light microscope. Results: There was a significant difference in ASP and METRNL immunoreactivity among all the groups included in the study (p < 0.001). Cancer tissues with Grade 1, 2 and 3 showed a significant increase in ASP and METRNL immunoreactivity compared with the control group; however, no significant difference was noted among the cancer tissues with Grade 1, 2 and 3. Conclusions: ASP and METRNL immunoreactivity increased at the cellular level in invasive ductal breast cancer, but there was no difference in immunoreactivity among the breast cancer grades. Highlights: Invasive ductal carcinoma is the most commonly diagnosed breast cancer. Asprosin and Meteorin-like protein are adipokines secreted by white adipose tissue. Asprosin and Meteorin-like protein immunoreactivity is increased at the cellular level in invasive ductal breast cancer. There was no difference in asprosin and Meteorin-like protein immunoreactivity between breast cancer grades.